Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Videos|April 1, 2022
Clinical Experiences of Using Circulating Tumor DNA
Author(s)Mary Scoviak, Managing Editor
In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).
Advertisement
Advertisement
Related to this article
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
Improving Early Identification and Escalation of HS
4
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
5